Read this company snapshot
Daily valuation snapshot
Silence Therapeutics Plc American Depository Share: source evidence dated 2026-10-09.
- Daily close (USD)
- $9.86
- Market capitalization (USD)
- $465,852,254.94
- Price / earnings (TTM)
- Not reported
- Price / book
- 12.11
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SLN in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research SLN in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing SLN with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $9.86 |
| Market capitalization (USD) | $465,852,254.94 |
| Price / earnings (TTM) | Not reported |
| Price / book | 12.11 |
No matching rows. Clear the filter to see all records.
Read SLN's valuation metrics
Company size
Silence Therapeutics Plc American Depository Share's recorded market capitalization is $465,852,254.94. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
SLN's recorded price-to-book ratio is 12.11. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Silence Therapeutics Plc American Depository Share with Aurora
Use the snapshot above to ask a specific question about SLN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow SLN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.